Yay.
FDA are under their own great pressure to find a mass-uptake non-addictive safe and efficacious long-lasting chronic pain therapeutic. They will probe and monitor intensely for weaknesses in Zilosul, but torpedo'ing efficacy of this promising drug candidate is in nobodies interest. If Zilosul is sold with a safety warning about adrenal issues, so be it. Other FDA-approved pharmaceuticals carry warnings of much worse.
If I didn't think this, there'd be a Dungiven-shaped hole in the nearest wall and I would be out of here for good.
2x2 Yay Or Nay From The FDA?, page-9
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.7M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.5¢ | $112.3K | 450.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 322039 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 46325 | 3 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |